• RenovoRx completed patient enrollment in its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, moving the program into final follow-up.
• Results have not been presented; top-line data is expected in the second half of 2027 once the study reaches its required number of events.
• The trial tests whether targeted intra-arterial delivery of gemcitabine using the RenovoCath device can improve overall survival versus standard intravenous chemotherapy.
• RenovoCath is already FDA-cleared, positioning the readout as a key catalyst for broader adoption of the company’s drug-device treatment approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110830PRIMZONEFULLFEED9807481) on August 11, 2026, and is solely responsible for the information contained therein.